Could STAT3 Be a Key to Curing Cancer?
Date
July 9, 2026
Date
July 9, 2026
Medical providers featured in this article
In Brief
- STAT3 is an important mechanism in the proliferation of cancerous tumor cells.
- Cedars-Sinai investigator James Turkson has identified compounds that successfully inhibit STAT3 activity, arresting tumor cell growth and causing apoptosis.
- Turkson's findings may be relevant to numerous cancer types.
For 25 years, Cedars-Sinai research scientist James Turkson, PhD, has single-mindedly pursued drug candidates targeting signal transducer and activator of transcription 3 (STAT3)—a protein that plays an important role in the proliferation and protection of cancerous tumor cells.
{{providers}}
In 2001, Turkson was lead author on the first study to identify an inhibitor that targeted STAT3 directly. In the intervening quarter century, his laboratory has developed several compounds that have been proven in vitro to effectively inhibit STAT3.
“These compounds strongly turn off STAT3 in tumor cells,” Turkson said. “And our studies validate that turning off STAT3 arrests tumor cell growth and causes apoptosis.”
Why Is STAT3 So Important in Tumor Biology?
STAT3 is a transcription factor that supports the growth, division, survival and immune response of healthy cells. In tumor cells, however, it can become chronically active, promoting cell proliferation, suppressing the body’s immune response and preventing apoptosis.
Our studies validate that turning off STAT3 arrests tumor cell growth and causes apoptosis.
“Normally, STAT3 turns off after it has completed its role,” said Turkson. “But we found that in cancer, it’s always turned on and programs cells to keep dividing and growing.”
{{cta-block}}
Because STAT3 controls multiple cancer-driving processes, it has been viewed as a high-value target by anti-cancer researchers. But so far it has resisted attempts to develop drugs that directly inhibit its activity, causing some to call it “undruggable.”
Turkson has developed azetidine compounds to inhibit STAT3 and tested their efficacy in models of melanoma and breast, blood, brain and pancreatic cancers. He is now refining a candidate compound, H182, using a nanoparticle system to protect the drug and deliver it to tumor cells.
Natural Compounds and STAT3: The Potential of R001
R001 is a hirsutinolide oil extracted from the ironweed plant that’s used as traditional medicine in parts of Southeast Asia, India and South America. In a 2022 study, Turkson and his lab showed that R001 repressed the co-opted antioxidant mechanism used by triple-negative breast cancer cells with chronically expressed active STAT3 to protect themselves against oxidative stress.
“Tumor cells have high metabolic activity. To survive, they rely on enhanced antioxidant mechanisms,” Turkson said. “But we have found that R001 interferes with those defenses, leading to cell death.”
Good Manufacturing Practice-certified R001 is in short supply. Turkson is developing a chemical derivative. Concurrently, he hopes to establish a clinical trial using the natural product.
“I have been driven to continue this work for so many years because I believe success against STAT3 in tumors could provide a significant leap forward in the treatment of a number of cancers and immune-related diseases,” he said.
